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Endothelial cells (ECs) are quiescent for years but can plastically switch to angiogenesis. Vascular sprouting
relies on the coordinated activity of migrating tip cells at the forefront and proliferating stalk cells that elon-
gate the sprout. Past studies have identified genetic signals that control vascular branching. Prominent are
VEGF, activating tip cells, and Notch, which stimulates stalk cells. After the branch is formed and perfused,
ECs become quiescent phalanx cells. Now, emerging evidence has accumulated indicating that ECs not only
adapt their metabolism when switching from quiescence to sprouting but also that metabolism regulates
vascular sprouting in parallel to the control by genetic signals.
Blood vessels arose in evolution for various reasons. First and
foremost, they supply oxygen, nutrients, and growth factors to
tissues while draining toxic metabolic waste. They also ensure
immune surveillance, thus allowing immune cells to patrol the
organism for foreign antigens or invaders. Interestingly, vessels
are evolutionarily closely associated with organismal meta-
bolism. Indeed, in primitive invertebrates, blood vessels were
initially hollow matrix tubes that were not lined by endothelial
cells (ECs), thus allowing only slow, sluggish, turbulent blood
flow and limited tissue perfusion (Mun˜oz-Cha´puli et al., 2005).
Only when organisms required a more rapid metabolism (for
instance, to predate) did vessels become lined by ECs in order
to establish faster laminar blood flow and more efficient perfu-
sion (Mun˜oz-Cha´puli et al., 2005). However, how ECs rewire their
own metabolism when switching from quiescence to vascular
branching and whether such metabolic adaptations affect
vascular branching remain much less studied.
ECs are highly plastic cells and can rapidly switch from a
long-term quiescent state to active growth upon stimulation by
hypoxia or growth factors. According to the prevalent model of
vascular sprouting (Potente et al., 2011), an endothelial tip cell
takes the lead by navigating at the vascular forefront. Following
the tip cell, endothelial stalk cells elongate the branch by
proliferating, whereas endothelial phalanx cells line quiescent
perfused vessels. The process of tip and stalk cell differentiation
is under the tight control of VEGF and Notch signaling and other
genetic signals (Potente et al., 2011). VEGF promotes tip cell
induction and filopodia formation and induces the expression
of the Notch ligand Delta-like 4 (DLL4), which activates Notch
signaling in neighboring cells and thereby suppresses VEGF
receptor 2 (VEGFR-2) expression and tip cell behavior
(Figure 1A). Tip and stalk cells do not exhibit permanently fixed
cell fates but dynamically switch between tip and stalk cell
phenotypes (Jakobsson et al., 2010). In a matter of hours, a tip
cell that lacks the fitness to compete for the leading position
can be overtaken by a stalk cell, which then acquires a tip posi-
tion. This mechanismmay ensure that vessel branching relies on
the fittest cells. However, little is known about the different meta-
bolic characteristics and requirements of these various EC sub-
types and whether Notch controls metabolism in ECs. First, we
will overview our current understanding of the various metabolic
pathways in ECs, and then we will discuss how these pathways
regulate vessel sprouting, illustrating amajor role for glycolysis in
this process.
Metabolic Pathways in Endothelial Cells
Glucose Uptake and Transport
Glucose delivery to peripheral organs occurs via paracellular
transport aswell as a transcellular route. In fact, only a small frac-
tion of the glucose that is taken up by ECs is phosphorylated for
further internal metabolization. ECs take up glucose through
facilitated diffusion, an energy-independent process facilitated
by glucose transporters (GLUT), mainly by GLUT-1. VEGF
increases GLUT-1 expression in ECs through the activation of
PI3K-AKT signaling (Yeh et al., 2008). Reduced GLUT-1 levels
in ECs decrease glucose uptake in peripheral organs (Huang
et al., 2012). In humans, impaired glucose transport across the
blood-brain barrier due to GLUT-1mutations causes the glucose
transporter protein syndrome, which is characterized by infantile
seizures, developmental delay, andmicrocephaly (Klepper et al.,
1999). GLUT-1 mutations have also been linked to learning
disability and Alzheimer’s disease (Guo et al., 2005; Shulman
et al., 2011). In ECs of intact coronary arteries, glucose is taken
up at the periphery of the cell and accumulates close to cell-to-
cell junctions, where the majority of glucose transporters are
anchored. This compartmentalization of glucose produces a
concentration gradient between the cytosol and the interstitial
space that might facilitate transcellular transport of glucose
(Gaudreault et al., 2008).
Divergent effects of insulin on glucose uptake andmetabolism
in ECs have been reported (Artwohl et al., 2007; Gaudreault et al.,
2008; Gerritsen et al., 1988;Wu et al., 1994). Insulin signaling and
insulin-induced phosphorylation of endothelial nitric-oxide syn-
thase (eNOS) in ECs control glucose uptake via skeletal muscle
cells (Kubota et al., 2011). The vascular effects of insulin rely on
the production of nitric oxide (NO), which promotes capillary
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recruitment, vasodilation, and perfusion, altogether enhancing
glucose disposal in skeletal muscle (Muniyappa and Quon,
2007). Insulin also signals in ECs in order to facilitate its own
transendothelial transport to perivascular organs (Barrett and
Liu, 2013; Kubota et al., 2011).
Endothelial Cells Are Addicted to Glycolysis
After glucose is taken up inside the cell, it is metabolized to
pyruvate in the glycolytic pathway (Figure 2). ECs line blood ves-
sels and have immediate access to oxygen in the blood, which
could promote mitochondrial respiration. Nonetheless, most
studies report that ECs do not rely on oxidative metabolism
but are highly glycolytic, generating more than 80% of their
ATP in this pathway (Culic et al., 1997; De Bock et al., 2013;
Kru¨tzfeldt et al., 1990). In the presence of physiological glucose
concentrations, only <1% of pyruvate generated in glycolysis is
oxidized in the tricarboxylic acid (TCA) cycle (De Bock et al.,
2013). However, when glucose and glycolysis levels drop, the
oxidation of glucose (as well as of palmitate and amino acids)
is enhanced, indicating that ECs switch to oxidative metabolism
when anaerobic glycolysis is impaired (known as the Crabtree
effect) (Kru¨tzfeldt et al., 1990).
ECs increase their glycolytic flux when switching from quies-
cence to proliferation and migration (De Bock et al., 2013). In
pathological conditions, such as pulmonary hypertension or
latent infection with Kaposi’s sarcoma-associated herpesvirus,
glycolysis is increased while oxygen consumption is reduced in
ECs (Delgado et al., 2010; Fijalkowska et al., 2010). Thus, ECs
metabolically resemble other rapidly proliferating healthy and
malignant cell types (Dang, 2012; Marelli-Berg et al., 2012;
Mullen and DeBerardinis, 2012; Vander Heiden et al., 2011).
Consequently, reducing glycolysis by silencing phospho-
fructokinase-2/fructose-2,6-bisphosphatase 3 (PFKFB3), which
generates fructose-2,6-bisphosphate, a potent allosteric acti-
vator of phosphofructokinase-1 (PFK1), impairs EC proliferation,
migration, and vascular sprouting in vitro (De Bock et al., 2013).
Also, the genetic deficiency of PFKFB3 in ECs causes vascular
hypobranching in mice (De Bock et al., 2013).
Similar to fibroblasts (Lemons et al., 2010; Valcourt et al.,
2012), ECs have substantial baseline glycolysis levels when
they are quiescent and only double their glycolysis flux when
they are activated to divide and migrate (De Bock et al.,
2013). Accordingly, when vessel sprouting is stimulated in hyp-
oxic conditions, ECs enhance glycolysis by no more than 50%
(Dobrina and Rossi, 1983). Thus, ECs differ from immune cells,
which have negligible glycolysis in their quiescent nonactivated
state and upregulate glycolysis by 20- to 30-fold upon activa-
tion (Frauwirth et al., 2002; Wang et al., 2011b). Rather, like
quiescent fibroblasts (Lemons et al., 2010; Valcourt et al.,
2012), ECs need a high baseline glycolysis level for homeostatic
maintenance, and blocking glycolysis by 80% by 2-deoxy-D-
glucose is toxic for these cells (Merchan et al., 2010; Wang
et al., 2011a).
Glycolysis levels are subject to environmental conditions
and molecular signals. Arterial, venous, microvascular, and
lymphatic ECs are all glycolytic (De Bock et al., 2013), but, in
comparison to rapidly proliferating, highly glycolytic microvas-
cular ECs, arterial ECs that grow more slowly are less glycolytic
but consume more oxygen, though it remains to be determined
to what extent adaptation to cell culture conditions influences
these results (Parra-Bonilla et al., 2010). Hemodynamic forces
such as blood flow also stimulate glycolysis through shear forces
acting on the EC glycocalyx (Sua´rez and Rubio, 1991). The
proangiogenic molecules VEGF and FGF2 increase PFKFB3-
driven glycolysis, whereas DLL4, which activates Notch
signaling and decreases branching, reduces glycolysis in ECs
(De Bock et al., 2013).
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Figure 1. Metabolic Fitness Influences
Vessel Branching
(A) A schematic of a tip (green) and a stalk (yellow)
cell in a vascular sprout. The tip cell extends
numerous filopodia in order to sense the environ-
ment. In response to the VEGF gradient (orange),
the tip cell upregulates Notch ligand Delta-like 4
(DLL4), which activates Notch signaling in the stalk
cell and promotes stalk cell formation by down-
regulating VEGFR-2. The activation of VEGFR
signaling by VEGF upregulates PFKFB3 levels and
glycolysis, whereas Notch intracellular domain
(NCID, active Notch) lowers PFKFB3 expression
and glycolytic flux.
(B) A schematic of mosaic spheroid assay, in
which ECs compete for the tip cell position when
forming vascular sprouts. By using spheroids
containing ECs of two different genotypes, it is
possible to determine which EC is at the tip cell
position.
(C) A schematic illustrating a tip and stalk cell in
a vascular branch of a mosaic spheroid (top)
and zebrafish intersomitic vessels (ISVs, bottom)
showing that, in comparison to wild-type (WT) cells
(green), cells overexpressing NICD (yellow cell,
left) are more frequently present in the stalk.
However, when NICD-overexpressing cells also
overexpress PFKFB3, these cells can compete
again for the tip position (yellow cell, right). Thus,
PFKFB3 overexpression overrules the stalk-cell-
inducing activity of NICD.
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At first sight, it may seem paradoxical that quiescent ECs rely
on glycolysis, given that they could take advantage of the avail-
able oxygen in their immediate environment in the blood to more
efficiently generate ATP via oxidative phosphorylation. Indeed,
per glucose molecule, glycolysis produces a net total of only
two molecules of ATP, whereas glucose oxidation yields up to
36 molecules of ATP. Nonetheless, one of the prime tasks of
ECs is to vascularize avascular tissues through sprouting. If
they relied primarily (or solely) on oxidative metabolism, then
ECswould be unable to generate ATP in oxygen-depleted areas.
In fact, given that interstitial oxygen levels drop faster than
glucose levels over a distance away from a blood vessel, ECs
can continue to rely on anaerobic glycolysis in such conditions
(Buchwald, 2011; Gatenby and Gillies, 2004). Indeed, ECs are
resistant to hypoxia as long as glucose is available but become
sensitive to oxygen deprivation when glucose is limiting (Mertens
et al., 1990). Another reason is that glycolysis rapidly generates
ATP, which ECs need in order to form highly motile and rapidly
moving lamellipodia and filopodia. Moreover, as long as glucose
is not limiting in the extracellular milieu, glycolysis can generate
similar amounts of ATP as glucose oxidation (Locasale and
Cantley, 2011). Another advantage of glycolytic metabolism is
that glycolysis and its side pathways generate the necessary
precursors for macromolecules needed in order for ECs to
grow, divide, and migrate (see below). Also, a low-oxidative
metabolism generates fewer reactive oxygen species (ROS)
and less oxidative stress in the high-oxygen environment that
quiescent ECs are exposed to. Finally, by consuming less oxy-
gen, they can transfer more oxygen to perivascular cells, thereby
improving tissue oxygenation.
ECs also store intracellular glucose reserves as glycogen
(Amemiya, 1983; Numano et al., 1974; Viza´n et al., 2009). How-
ever, glycogen breakdown only becomes significant in
glucose-deprived conditions and not in hypoxia, although it is
not clear whether glycogenolysis is used for bioenergetic pur-
Figure 2. Schematic of Endothelial Cell
Metabolism
A simplified schematic of EC metabolism showing
the knownmetabolic pathways inECsand their rate-
limiting metabolic enzymes. a-KG, a-ketoglutarate;
Ac-CoA, acetyl coenzyme A; AR, aldolase re-
ductase; F2,6P2, fructose-2,6-bisphosphate; F6P,
fructose-6-phosphate; FBP, fructose-1,6-bisphos-
phate; G6P, glucose-6-phosphate; G6PD, glucose-
6-phosphate dehydrogenase; GFAT, glutamine
fructose-6-phosphate amino-transferase; Gln,
glutamine; GLS, glutaminase; Glu, glutamate; GSH,
glutathione; GSSG, glutathione disulfite; 3PG,
glyceraldehyde-3-phosphate; HK, hexokinase;
LDH, lactate dehydrogenase; MCT, monocarboxy-
late transporter; OAA, oxaloacetate; Orn, ornithine;
PFK, phosphofructokinase; PFKFB3, phosphofruc-
tokinase-2/fructose-2,6-bisphosphatase isoform 3;
R5P, ribose-5-phosphate; TKT, transketolase; TCA,
tricarboxylic acid; UDP-GlcNAc, uridine diphos-
phate N-acetylglucosamine.
poses alone (Kru¨tzfeldt et al., 1990; Viza´n
et al., 2009). In cerebral microvascular
ECs, norepinephrine induces glycogenol-
ysis, whereas 5-hydroxytryptamine stimu-
lates glycogenesis (Spatz et al., 1986). Overall, little is known
about the role and importance of glycogen in ECs, but the inhibi-
tion of glycogen phosphorylase impairs EC viability and migra-
tion (Viza´n et al., 2009). This raises the question of whether
ECs use this endogenous glucose storage to sprout into avas-
cular glucose-deprived areas.
Pentose Phosphate Pathway
The pentose phosphate pathway (PPP) is a side branch of glycol-
ysis that cells use for divergent purposes (Figure 2). In this
pathway, glucose-6-phosphate is oxidized to pentose sugars
and reduces equivalents in two phases. The irreversible oxida-
tive branch (oxPPP) generates NADPH and ribose-5-phosphate
(R5P), whereas the reversible nonoxidative arm (non-oxPPP)
produces only R5P. The latter is used for the synthesis of nucle-
otides, whereas NADPH is used for the reductive biosynthesis of
lipids, production of NO, or reconversion of oxidized glutathione
(GSSG) to reduced glutathione (GSH), a major cellular redox
buffer. Depending on the cellular needs and context, the PPP
can serve to promote cellular growth and division by increasing
the biosynthesis of macromolecules (Cairns et al., 2011; Lunt
and Vander Heiden, 2011; Vander Heiden et al., 2009), or the
oxPPP can ensure redox homeostasis (Anastasiou et al.,
2011). As rate-limiting enzymes, glucose-6-phosphate dehydro-
genase (G6PD) controls the oxPPP arm, whereas transketolase
(TKT) regulates the non-oxPPP branch. A recent study high-
lighted that ECs possess additional mechanisms for maintaining
the redox balance. Indeed, ECs express UBIAD1, a nonmito-
chondrial prenyltransferase that synthesizes the electron carrier
CoQ10 in the Golgi membrane compartment in order to prevent
lipid peroxidation and protect membranes from oxidative dam-
age (Mugoni et al., 2013).
Of all the glucose utilized by ECs, only 1%–3%normally enters
the PPP in physiological conditions (Dobrina and Rossi, 1983;
Jongkind et al., 1989; Kru¨tzfeldt et al., 1990; Spolarics and Spit-
zer, 1993; Viza´n et al., 2009). However, in conditions of increased
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oxidative stress, such as after treatment with lipopolysaccharide
in vivo (Spolarics and Spitzer, 1993) or methylene blue in vitro
(Dixit et al., 2008; Kru¨tzfeldt et al., 1990), up to 80% of glucose
can enter the PPP, allowing cells to sustain GSH levels in order
to reduce possibly harmful ROS (Spolarics and Wu, 1997).
G6PD overexpression in ECs also increases NADPH and NO
production and maintains intracellular glutathione stores when
exposed to oxidants (Leopold et al., 2003b). The ability to acti-
vate the oxPPP enables quiescent ECs to better survive and
tolerate oxidative stress during hypoxia reoxygenation events
(Buderus et al., 1989). By activating protein kinase A, high
glucose levels impair G6PD activity in ECs, thereby decreasing
cell survival because of insufficient redox control (Zhang et al.,
2000). A reduction of G6PD expression in vivo increases ROS
levels and decreases eNOS activity in the aorta, thereby
reducing vascular reactivity (Leopold et al., 2007).
The PPP might also influence vascular sprouting via other
mechanisms. First, G6PD can modulate VEGF signaling, as
revealed by findings that inhibition of G6PD impairs and G6PD
overexpression promotes angiogenesis in vitro by regulating
NO production via VEGF and tyrosine phosphorylation of
VEGFR-2 (Leopold et al., 2003a; Viza´n et al., 2009). In a positive
feedback, the proangiogenic factor VEGF increases the oxPPP
flux (Viza´n et al., 2009) and enhances G6PD activity and localiza-
tion at the plasma membrane (Pan et al., 2009). Second, the
non-oxPPP can promote angiogenesis via the production of
macromolecules, explaining why the inhibition of TKT reduces
EC viability and migration (Viza´n et al., 2009). Third, because
low amounts of ROS can be proangiogenic (Okuno et al.,
2012), hereditary G6PD deficiency in diabetes patients promotes
the development of ocular neovascularization, presumably by
increasing ROS levels as a result of the decreased production
of NADPH (Cappai et al., 2011). Fourth, insulin may regulate
NO generation in ECs by stimulating oxPPP and NADPH produc-
tion, which is required for NO synthesis (Wu et al., 1994). Overall,
the role of the oxPPP in vessel sprouting and maintenance is
contextual, and understanding its role and regulation requires
further study.
Hexosamine Biosynthesis Pathway
A fraction of glucose can also flux through the hexosamine
biosynthesis pathway (HBP), where it is used for protein glyco-
sylation (Figure 2). The rate-limiting step is catalyzed by glutami-
ne:fructose-6-phosphate amidotransferase, which regulates the
HBP in order to produce UDP-N-acetylglucosamine (UDP-
GlcNAc), a substrate used for N-linked and O-linked glycosyla-
tion (Hart et al., 2007; Helenius, 1994; Love and Hanover,
2005). Because the HBP depends on the availability of glucose,
glutamine, acetyl-CoA, and ATP, it is considered to be a ‘‘nutrient
sensor’’ (Zachara and Hart, 2004a, b). Despite its presumed
importance in regulating glycosylation, only a few reports stud-
ied the role of the HBP or glycosylation in angiogenesis. For
instance, 2-deoxy-D-glucose inhibits angiogenesis by interfering
with N-linked glycosylation (Merchan et al., 2010), whereas
elevated protein O-GlcNAc modification in ECs impairs angio-
genesis, possibly by inhibiting AKT signaling (Luo et al., 2008).
Furthermore, by interacting with N-glycans of VEGFR-2,
galectin-3 facilitates VEGFR-2 plasma membrane retention
and phosphorylation and thereby stimulates VEGF-mediated
angiogenesis (Markowska et al., 2011). Glycoproteins bearing
N-linked oligosaccharides are essential for capillary tube forma-
tion (Nguyen et al., 1992) and the formation of the glycocalyx
layer, which acts as a mechanosensor and controls EC perme-
ability (Curry and Adamson, 2012). Also, glycosylation of the
Notch receptor determines its responsiveness toward its ligands
DLL4 and Jagged1, thereby playing a crucial role in tip-stalk cell
differentiation during vessel branching (Benedito et al., 2009).
Whether glycosylation of the angiogenic receptor is dynamically
controlled through the HBP and whether those changes are
dependent on nutrient availability and sensing awaits further
insight.
Polyol Pathway
Hyperglycemia promotes vascular complications in diabetes.
When glucose is present in excess of what the glycolytic
pathway can handle, glucose enters the polyol pathway, a
two-step pathway in which aldose reductase reduces glucose
to sorbitol, which is then converted to fructose (Lorenzi, 2007;
Tang et al., 2012) (Figure 2). Because the aldose reductase reac-
tion converts NADPH to NADP+, the activation of the polyol
pathway can deplete stores of NADPH, which are necessary
for maintaining reduced GSH levels for redox homeostasis,
thus leading to the accumulation of ROS. It is unknown to what
extent the accumulation of polyols themselves can also be toxic.
In humans, high levels of aldose reductase are associated with
toxicity. Human aldose reductase transgene expression in ECs
in low-density lipoprotein receptor knockout mice (a model of
atherosclerosis) aggravated vascular disease in diabetic condi-
tions (Vedantham et al., 2011). Conversely, pharmacologic inhi-
bition of the aldose reductase reduced EC oxidative damage and
apoptosis in vitro and retinal vascular overgrowth through the
upregulation of VEGF in diabetic rats and mice in vivo (Obrosova
and Kador, 2011; Oyama et al., 2006), whereas aldose reductase
deficiency diminished retinal vascular changes in a model of
oxygen-induced retinopathy (Fu et al., 2012). Whether aldose
reductase is a target in humans remains debated. Normal polyol
pathway activity is also required for physiological angiogenesis
by affecting VEGFR-2 and FGF signaling (Tammali et al., 2011;
Yadav et al., 2012).
Mitochondria and Respiration in ECs
Unlike other glycolysis-addicted cell types such as red blood
cells (lacking mitochondria) or embryonic stem cells (containing
few inactivemitochondria) (Kondoh et al., 2007), ECs have active
mitochondria, but they contain fewer mitochondria than oxida-
tive cell types. Indeed, mitochondria make up only 5% of the
cellular volume, in contrast to 30% in hepatocytes (Blouin
et al., 1977). With gestational age during embryonic develop-
ment, respiratory chain complexes and oxidative phosphoryla-
tion are reduced, whereas glycolytic activity is increased in
ECs, presumably to cope with the metabolic stress during birth
and render ECs less susceptible to peripartum hypoxic damage
(Illsinger et al., 2011). Vascular branching signals also regulate
mitochondrial biogenesis. Indeed, VEGF stimulates mitochon-
drial biogenesis via AKT-dependent signaling (Wright et al.,
2008), whereas the silencing of SIRT1, a negative regulator
of the Notch pathway (Guarani et al., 2011) (thus leading to
enhanced Notch signaling and reduced vessel branching),
inhibits mitochondrial biogenesis in ECs (Csiszar et al., 2009).
However, whether mitochondrial biogenesis influences vessel
sprouting and how it may do so remain to be assessed. Notably,
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ATP derived from glycolysis is essential for maintaining the mito-
chondrial network (Giedt et al., 2012).
In vitro, ECs consume relatively low amounts of oxygen, which
allows them to transfer most of the oxygen that enters these cells
to perivascular cells in vivo (Figure 3) (Helmlinger et al., 2000).
However, in vivo measurements documented a drop of oxygen
levels across the arteriolar vessel wall (Tsai et al., 1998; Tsai
et al., 2003). Though the cellular source consuming oxygen
(ECs versus smooth muscle cells) was not identified, these
studies postulated that the vessel wall can act as an ‘‘oxygen
sink’’ to prevent the exposure of perivascular tissues to high
oxygen levels and oxidative damage, though these observations
are debated (Golub et al., 2011).
Primarily, mitochondria in ECs are generally considered to
have a signaling function (via the production of proangiogenic
ROS levels and NO) rather than serving as a bioenergetic
powerhouse (Davidson, 2010; Quintero et al., 2006) (Figure 3).
For instance, ECs detect mechanical stress by transmitting
force via the cytoskeleton to the mitochondria and triggering
mitochondrial ROS signaling, leading to an increase in the
expression of NF-kB and VCAM-1 (Ali et al., 2004). Mitochon-
dria have also been implicated as regulators of ion (H+ and
Ca2+) homeostasis and apoptosis in ECs. Indeed, exposure of
ECs to high levels of glucose (as occurs in diabetes) enhances
mitochondrial fission and/or reduces mitochondrial fusion,
resulting in mitochondrial fragmentation, ROS production, and
Ca2+ overload, altogether leading to EC dysfunction and death
(Pangare and Makino, 2012). Prohibitin 1 (PHB1), a protein
localized to the inner mitochondrial membrane, inhibits mito-
chondrial complex I and thereby prevents ROS-induced senes-
cence as well as AKT-dependent Rac1 hyperactivation, which
leads to cytoskeletal rearrangements, decreased EC motility,
and impaired capillary tube formation. Thus, PHB1 is important
for proper mitochondrial function and maintaining the angio-
genic capacity of ECs (Schleicher et al., 2008). Because of their
role in signaling rather than in bioenergetics, mitochondria in
ECs have been considered targets for angiogenesis inhibition
(Park and Dilda, 2010).
Figure 3. Mitochondria and Respiration in
Endothelial Cells
Despite having immediate access to oxygen in the
blood, ECs rely on glycolysis to generate ATP.
Mitochondria in ECs are not considered important
bioenergetic powerhouses but, rather, act pri-
marily as signaling organelles by generating
proangiogenic reactive oxygen species (ROS) and
nitric oxide (NO). Moreover, by utilizing low
amounts of oxygen, they ensure oxygen diffusion
across the endothelial barrier to the perivascular
tissues.
In line with findings that mitochondria
in ECs are not bioenergetic power-
houses, oxidative pathways only ac-
count for 15% of the total amount of
ATP generated in ECs (De Bock et al.,
2013). Also, mitochondrial respiration
poisons that reduce oxygen consump-
tion do not impair vessel branching,
whereas the supplementation of NADH or pyruvate, which
increase oxygen consumption, do not stimulate vascular
sprouting (De Bock et al., 2013). Nonetheless, mitochondria
in ECs have a high bioenergetic reserve capacity and can
increase respiration substantially in stress conditions of glucose
deprivation or oxidative stress (Dranka et al., 2010; Mertens
et al., 1990). An exception may be the quiescent ECs of the
blood-brain barrier, which have up to 5-fold more mitochondria
than ECs in peripheral organs, presumably to provide large
amounts of energy for transport of nutrients and ions across
the blood-brain barrier in order to ensure brain homeostasis
(Oldendorf and Brown, 1975).
Fatty Acid Metabolism
The role of other metabolic pathways in ECs remains poorly
characterized. Some studies report that fatty acid oxidation
(FAO) is a critical bioenergetic supply pathway for ECs (Figure 2),
especially when carnitine is supplemented (Dagher et al., 1999,
2001; Hu¨lsmann and Dubelaar, 1988, 1992) or glucose is
removed from the medium (Dagher et al., 2001; Kru¨tzfeldt
et al., 1990). In the latter condition, an increase in FAO compen-
sates for the lack of glycolytic ATP production. Carnitine palmi-
toyl transferase 1 is a rate-limiting enzyme of FAO whose activity
is inhibited by malonyl-CoA, itself produced by acetyl-CoA
carboxylase (ACC). By inactivating ACC, AMPK stimulates
FAO in ECs (Dagher et al., 2001; Fisslthaler and Fleming,
2009). ECs can oxidize both extra- and intra-cellular fatty acids,
though the relative contribution of FAO versus glycolysis to ATP
generation in ECs is debated (Dagher et al., 1999, 2001; Delgado
et al., 2010; Dobrina and Rossi, 1983; Polet and Feron, 2013;
Spolarics et al., 1991). In glucose-deprived or matrix-detached
tumor cells, FAO produces metabolites for the TCA cycle, and
these metabolites generate citrate and malate; i.e., substrates
of the NAPDH-producing isocitrate dehydrogenase and malic
enzyme, respectively (Jeon et al., 2012; Pike et al., 2011). Hence,
by indirectly generating NADPH needed to convert GSSG to its
reduced form (GSH), FAO regulates redox homeostasis and pre-
vents excessive oxidative stress (which is antiangiogenic) (Jeon
et al., 2012; Pike et al., 2011), but such a role has not been
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described in ECs. The bioenergetic importance of FAO for vessel
branching remains unknown.
Fatty-acid-binding protein 4 (FABP4), an intracellular lipid
chaperone, is a target of VEGF and stimulates EC proliferation
in vitro (Elmasri et al., 2009), whereas the loss of FABP4 impairs
VEGF transgene-induced neovascularization in airways, in part
by decreasing VEGF-induced EC proliferation and lowering
eNOS and stem cell factor expression (Ghelfi et al., 2013).
Also, more FABP4-immunoreactive vessels are detected in
bronchial biopsies of patients with asthma (Ghelfi et al., 2013).
Notably, VEGF-B promotes endothelial lipid uptake and trans-
port to peripheral tissues (heart and skeletal muscle) through
the upregulation of the expression of fatty acid transporters
FATP3 and FATP4 (Hagberg et al., 2010). In addition, VEGF-B
stimulates AMPK required for aortic EC proliferation in vitro inde-
pendently of an increase in FAO (Reihill et al., 2011). In agree-
ment with findings that ectopic lipid deposition is associated
with the pathogenesis of type II diabetes, neutralizing VEGF-B
antibody restored insulin sensitivity and glucose tolerance by
reducing endothelial-to-tissue lipid transport, thereby creating
a novel option for diabetes therapy (Carmeliet et al., 2012; Hag-
berg et al., 2012).
Lipids are also required for the formation of membranes and
act as intracellular signaling molecules. The upregulation of lipid
metabolism is a hallmark of multiple cancer types (Biswas et al.,
2012; Santos and Schulze, 2012; Schug et al., 2012). The
expression of fatty acid synthase (FAS), which catalyzes de
novo lipid synthesis, is generally low or undetectable in adult
healthy tissues, given that the majority of fatty acids are taken
up from dietary sources. In contrast, even with an adequate
nutritional lipid supply, FAS is highly upregulated in cancer cells
to provide these rapidly proliferating cells with sufficient amounts
of lipids for membrane biogenesis and to confer them a growth
and survival advantage (Pandey et al., 2012; Santos and
Schulze, 2012). The role of lipogenesis in vascular branching
remains poorly studied. Pharmacological inhibition of FAS
inhibits tumor angiogenesis (Seguin et al., 2012), whereas the
genetic loss of endothelial FAS impairs pathological angiogen-
esis by decreasing plasma membrane targeting of eNOS (via
reduced palmitoylation) and VEGFR-2 (Wei et al., 2011).
A recent study showed that maintaining efficient cholesterol
efflux from ECs is essential for angiogenesis (Fang et al.,
2013). In order to prevent cholesterol overload in cells, ATP-
binding cassette transporters mediate cholesterol efflux from
cells to apolipoprotein A-I (apoA-I) and the apoA-I-containing
high-density lipoprotein. In ECs, cholesterol efflux reduces
membrane lipid rafts, which interferes with VEGFR-2 membrane
localization, dimerization, and endocytosis and impairs VEGF-
induced angiogenesis (Fang et al., 2013). Another apolipoprotein
(e.g., apoB), impairs angiogenesis by upregulating the antiangio-
genic VEGF trap VEGFR-1 (Avraham-Davidi et al., 2012). The
effects of apoB-containing lipoproteins on vessel growth were
not induced by a decreased delivery of fatty acids to tissues or
due to global lipid starvation, given that apoC-II deficiency did
not phenocopy the vascular defects resulting from the deficiency
of microsomal triglyceride transfer protein, which is involved in
the biosynthesis of apoB-containing lipoproteins. It remains to
be determined whether this mechanism underlies the EC
dysfunction that precedes the formation of atherosclerotic pla-
ques or impairs collateral vessel growth in hypercholesterolemic
patients.
Amino Acid Metabolism
Besides glucose, rapidly growing cancer cells and embryonic
stem cells also metabolize various types of amino acids, such
as glutamine, proline, and serine (Dang, 2012; DeBerardinis
and Thompson, 2012; Kalhan and Hanson, 2012; Phang and
Liu, 2012; Shyh-Chang et al., 2013) (Figure 2). Of these amino
acids, glutamine is a key metabolic fuel for proliferating cells.
The role of glutamine metabolism has not been studied exten-
sively in ECs, and, therefore, its role in angiogenesis remains
unclear. ECs take up glutamine via Na+-dependent transport
mechanisms but also have the capacity to produce this amino
acid via glutamine synthetase, though the physiological rele-
vance of this process for vessel branching remains unknown
(Lohmann et al., 1999). Glutamine taken up by ECs can be con-
verted to glutamate and ammonia (Wu et al., 2000) (Figure 2). The
activity of glutaminase 1, the first step in the glutaminolysis
pathway, is higher in ECs than it is in lymphocytes (Leighton
et al., 1987). Pharmacological inhibition of glutaminolysis impairs
the proliferative capacity of ECs and induces a senescent-like
phenotype in ECs (Unterluggauer et al., 2008). Nonetheless, it
is still debatedwhether glutamine oxidation contributes substan-
tially to ATP production in ECs (De Bock et al., 2013; Kru¨tzfeldt
et al., 1990; Spolarics et al., 1991; Wu et al., 2000). However,
glutamine contributes more significantly to ATP production and
promotes survival when oxidative stress impairs glucose-depen-
dent pathways of ATP production (Hinshaw and Burger, 1990),
indicating that the contribution of glutamine metabolism to ATP
production in ECs is contextual (De Bock et al., 2013; Kru¨tzfeldt
et al., 1990; Spolarics et al., 1991; Wu et al., 2000).
Glutamine also serves as a carbon source for the biosynthesis
of macromolecules, but stable isotope-tracer-based metabolo-
mic flux analysis of glutamine in ECS has not been performed
yet. Glutamine metabolism by ECs could also be important for
the provision of nitrogen for biosynthetic purposes. Indeed, the
synthesis of the polyamine precursor from glutamine sustains
EC growth (Wu et al., 2000) (Figure 2). Furthermore, glutamine
inhibits the endothelial production of NO, in part via the conver-
sion of glutamine to glucosamine in the HBP, which inhibits the
oxPPP activity and thereby reduces the availability of NADPH,
an essential cofactor for eNOS (Wu et al., 2001). Glutamine
also impairs NO production, inhibiting the formation of arginine
from citrulline through reducing citrulline transport (Kawaguchi
et al., 2005; Meininger and Wu, 1997; Sessa et al., 1990). Also,
arginine controls angiogenesis by regulating the levels of ROS
in ECs (Park et al., 2003; Zhuo et al., 2011). No studies have
been reported on the possible role of proline, serine, and threo-
nine metabolism in ECs.
Metabolic Changes during Vascular Sprouting
Migrating Tip and Proliferating Stalk Cells
In ECs, the tip-cell-activating signal VEGF increases glycolysis
by upregulating PFKFB3 levels, suggesting that tip cells require
elevated levels of PFKFB3-driven glycolysis (De Bock et al.,
2013) (Figure 1A). Accordingly, PFKFB3 silencing and/or deletion
impairs the formation of distal sprouts with tip cell filopodia and
the number of filopodia in retinal sprouting vessels and reduces
the lamellipodia area of cultured ECs (De Bock et al., 2013).
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However, aside from a role for PFKFB3 in tip cells, PFKFB3
also regulates stalk cell functions. Consistent with a reported
increase in glycolysis when cells enter S-phase (Almeida et al.,
2010), PFKFB3 silencing and/or deletion reduced EC prolifera-
tion in various angiogenesis assays in vitro and sprouting retinal
vessels in vivo (De Bock et al., 2013). DLL4-mediated Notch acti-
vation also lowered PFKFB3 levels and glycolysis (De Bock et al.,
2013) (Figure 1A). Yet, stalk cells proliferate in order to elongate
the stalk, and cell proliferation is known to require increased
levels of glycolysis (Vander Heiden et al., 2011). This paradox
is resolved by findings that the growth-inhibitory activity of Notch
is overruled by other genetic (Wnt) signals (Phng et al., 2009).
Notably, in mosaic sprouting assays (Figure 1B), the overexpres-
sion of PFKFB3 is able to overcome the pro-stalk-cell activity of
Notch and favors the tip localization of ECs overexpressing both
PFKFB3 and the transcriptionally active Notch domain NICD
when using an endothelial spheroid sprouting model in vitro or
analyzing vascular branching in zebrafish embryos in vivo (De
Bock et al., 2013) (Figure 1C). This is remarkable, given that no
other genetic signal has been shown to be able to overrule the
prostalk activity of Notch. Conversely, PFKFB3-silenced ECs
are less capable of competing for the tip position in mosaic
sprouting assays (De Bock et al., 2013). The consequences of
PFKFB3 blockade on tip and stalk cells is illustrated in Figure 4.
Overall, in parallel to genetic signals, PFKFB3-driven glycolysis
also regulates vascular branching.
Quiescent Phalanx Cells
Little is known about the metabolic changes that accompany,
promote, or are necessary for inducing EC quiescence. Glycol-
ysis is decreased in quiescent ECs, which might serve several
purposes. First, given that ECs rely on glycolysis in order to
divide, thus lowering glycolysis reduces proliferation and pro-
motes quiescence. Second, quiescent ECs are exposed to
high oxygen levels in the blood, whichmay cause oxidative dam-
age. Thus, similar to erythrocytes, quiescent ECs must protect
themselves against oxidative damage. By maintaining a low
oxidative metabolism, ECs minimize ROS production, thereby
providing protection against their high-oxygen milieu. Third, of
the total amount of glycolysis, ECs use 40% to proliferate and
migrate, whereas they use the remaining 60% for maintenance
homeostasis (De Bock et al., 2013), which is in line with findings
A B
Figure 4. PFKFB3 Blockade Impairs Tip and
Stalk Cell Behavior
(A) A schematic model demonstrating that, in
control WT conditions, stalk cells proliferate, and
tip cells migrate directionally, extend long motile
filopodia, and compete for the tip.
(B) Upon PFKFB3 blockade, stalk cells are hypo-
proliferative, whereas tip cells have impaired
migration and directional movement with short
immobile filopodia so that tip cells lose their
competitive advantage for the tip position.
that proliferation only requires a 30% in-
crease in ATP production (Kilburn et al.,
1969; Locasale and Cantley, 2011).
Quiescent ECs need this residual 60%
of glycolysis in order to perform energy-
demanding homeostatic maintenance
functions such as transendothelial transport, barrier formation,
glycocalyx deposition, and matrix production (Curry and Adam-
son, 2012; Potente et al., 2011)—resembling quiescent fibro-
blasts, which also have an active metabolism in baseline
conditions (Lemons et al., 2010). It has been postulated that
cellular quiescence requires a higher baseline metabolism than
previously anticipated to ensure maintenance of ion gradients,
protein and RNA synthesis, and other processes (Locasale and
Cantley, 2011). Overall, because of their particular milieu and
cellular activities, quiescent ECs adapt their metabolism to opti-
mally accommodate the need for reduced proliferation on one
side with the homeostatic needs for redox control and baseline
maintenance activities on the other side.
Compartmentalization of Metabolism
Tip cells extend lamellipodia and filopodia in order to migrate.
The formation of these motile structures relies on the remodeling
of the actin cytoskeleton, a process that requires the rapid pro-
duction of high amounts of ATP. In motile ECs, a large fraction of
the total amount of glycolytic ATP generated is utilized by the
actomyosin ATPase (Culic et al., 1997). In quiescent contact-
inhibited ECs, enzymes of the glycolytic cascade are primarily
present in the perinuclear cytosol. However, once they become
motile and start migrating, these glycolytic enzymes also
become translocated to lamellipodia, where they are highly
concentrated along with F-actin in membrane ruffles at the
leading front to generate high levels of ATP in lamellipodial
‘‘ATP hot spots’’—mitochondria are excluded from lamellipodia
and filopodia (De Bock et al., 2013) (Figures 5A–5D). Further-
more, biochemical analysis indicates that PFKFB3 is present in
F-actin-enriched fractions and to higher levels in proliferating
and migrating ECs (De Bock et al., 2013).
Various glycolytic enzymes are inactive as dimers but become
more active in a tetrameric configuration. Through actin
binding sites, these enzymes bind to actin, which stabilizes
their tetrameric configuration and enhances their enzymatic
activity (Real-Hohn et al., 2010) (Figure 5E). Such compartmen-
talization of glycolysis with the actin cytoskeleton offers various
advantages. High levels of ATP are rapidly generated in lamelli-
podia and filopodia at the site where energy is needed dur-
ing EC migration (Figures 5E and 5F). In addition, the rapid
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extension-retraction of filopodia and lamellipodia may create an
ATP drain for the cell body. Localizing ATP supply to compart-
ments where ATP is consumed can prevent catastrophic ATP
depletion for the cell. Moreover, through binding to actin, an
assembly line of the glycolytic machinery is generated wherein
the product of one glycolytic enzyme becomes the substrate of
its neighboring glycolytic enzyme because of their close prox-
imity (al-Habori, 1995; Fulgenzi et al., 2001; Lagana et al.,
2000; Real-Hohn et al., 2010). Motile structures in other organ-
isms, such as flagella in sperm and predatory tentacles in hydra,
also concentrate glycolytic enzymes (Baquer et al., 1975; Hereng
et al., 2011; Mitchell et al., 2005; Pavlova, 2010). The functional
relevance of this link is underscored by findings that a mutant
fruit fly expressing an aldolase variant that cannot bind actin is
unable to fly (Wojtas et al., 1997). In vascular smooth muscle
cells, glycolysis and gluconeogenesis occur in separate ‘‘com-
partments’’ because of the spatial separation of glycolytic and
gluconeogenic enzymes in distinct plasma membrane micro-
domains (Lloyd and Hardin, 2001). Whether a comparable
compartmentalization of glycolysis versus gluconeogenesis
occurs in ECs is unknown.
Feedback Regulation of Vascular Branching
by Metabolism
An intriguing question is whether metabolism provides a feed-
back for the genetic signals that control vascular branching.
One example is how Notch is subject to regulation by metabolic
signals in ECs. Indeed, Notch is a direct target of the NAD+-
dependent deacytelase SIRT1, a key regulator of cellular meta-
bolism that is activated by nutrient deprivation (Chalkiadaki
and Guarente, 2012; Guarani and Potente, 2010). By deacety-
lating NICD and thereby reducing its protein stability, SIRT1
reduces the amplitude and duration of the Notch response in
a negative feedback loop (Guarani et al., 2011). This promotes
the vascularization of the nutrient-deprived tissue. Accordingly,
in the absence of SIRT1 (a condition mimicking nutrient
abundance), ECs are sensitized to Notch signaling, resulting
in a stalk-cell-like phenotype with impaired vessel outgrowth
(Potente et al., 2007).
Another mechanism by which SIRT1 controls vascular sprout-
ing is via deacetylating the transcription factor FOXO1, which
controls cell growth and metabolism (Eijkelenboom and Burger-
ing, 2013). FOXO1 is activated by nutrient stress (and is a target
A
B
C
D
E
F
Figure 5. Compartmentalization of Metabolism
(A–C) Representative images of ECs expressing the ATP biosensor GO-ATeam (A), the glycolytic enzyme phosphoglycerate kinase (B), and the mitochondrial
marker TOMM20 (C), revealing high ATP levels and glycolytic enzymes in the perinuclear cytosol as well as at the membrane ruffles of lamellipodia, whereas
mitochondria are present around the nucleus but excluded from lamellipodia. Lamellipodia are denoted with a white dotted line.
(D) A schematic showing the localization of glycolytic enzymes in the perinuclear cytosol and the compartmentalization in lamellipodia and filopodia of the tip cell.
The mitochondria are excluded from the filopodia because they are too large to fit into the thin cytosolic protrusions.
(E) A schematic illustrating the compartmentalization of the glycolytic regulator PFK1 with F-actin. Actin binding stabilizes PFK1 in its tetrameric active
configuration.
(F) A schematic illustrating that the glycolytic enzymes are arranged in an assembly line, creating a ‘‘glycolytic hub.’’
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of SIRT1 and AMPK), but, unlike SIRT1, this transcription factor
inhibits vessel branching (Oellerich and Potente, 2012). Indeed,
loss of FOXO1 results in embryonic lethality because of vascular
abnormalities (Furuyama et al., 2004), and the inducible post-
natal deletion of FOXO1, FOXO2, and FOXO3 together induces
hemangioma formation (Paik et al., 2007). These data suggest
that a finely tuned balance between SIRT1 and FOXO1 is
required in order to orchestrate the vessel-branching response
to nutrient deprivation.
Metabolism has been shown to control growth factor signaling
in cancer cells (DeBerardinis and Thompson, 2012). Interest-
ingly, the response of Notch to its ligands DLL4 and Jagged1
is determined by the glycosylation state of its extracellular
domain in a tip-versus-stalk cell manner (Benedito et al., 2009),
thus providing another example of how metabolism impacts on
angiogenic signal transduction. In particular, glycosylation by
FRINGE glycosyltransferases favors the activation of Notch by
DLL4 over Jagged1 (Eilken and Adams, 2010). Even though stalk
cells primarily express Jagged1 (and tip cells predominantly
express DLL4), Jagged1 is only able to weakly activate Notch1
in comparison to DLL4 (Eilken and Adams, 2010). As a result,
DLL4 causes hypobranching, whereas Jagged1 induces oppo-
site effects. An outstanding question is whether the glycosylation
of other key angiogenic receptors (such as VEGFR-2) provides
another level of metabolic control of angiogenesis.
Metabolites as Angiogenic Signals
In the brain, muscle, and tumors, lactate is a fuel for neighboring
cells (Bergersen, 2007; Brooks, 2009; Draoui and Feron, 2011;
Whitaker-Menezes et al., 2011). This metabolite is generated
through the conversion of pyruvate, itself produced in the glyco-
lytic pathway (or other pathways) by lactate dehydrogenase A
(LDH-A). However, more than being a waste product, lactate
also serves as a fuel for oxidative metabolism after conversion
to pyruvate by LDH-B (Figure 2). For instance, in tumors,
lactate is oxidized by oxygenated tumor cells, thereby sparing
glucose for more hypoxic glycolytic cancer cells (Draoui and
Feron, 2011). Cancer-associated fibroblasts also have aerobic
glycolysis and extrude lactate to ‘‘feed’’ adjacent tumor cells
(Whitaker-Menezes et al., 2011). In the brain, a cell-to-cell lactate
shuttle between astrocytes and neurons is linked to glutamater-
gic signaling (Brooks, 2007). However, in ECs, only <1% of
glucose is oxidized in the TCA cycle, and glucose oxidation
generates only 6% of the total amount of ATP in ECs (De Bock
et al., 2013). Also, lactate is only a significant substrate for oxida-
tion in the absence of glucose in ECs (Kru¨tzfeldt et al., 1990).
Lactate in ECs can act as a signaling molecule rather than
a metabolic substrate. Indeed, lactate inhibits the activity of
the oxygen-sensing prolyl-hydroxylase domain protein PHD2,
thereby activating the hypoxia-inducible transcription factor
HIF-1a in normoxic oxidative tumor cells and triggering tumor
angiogenesis by upregulating VEGF and other proangiogenic cy-
tokines (De Saedeleer et al., 2012; Hunt et al., 2007). By inhibiting
PHD2, lactate also triggers the phosphorylation and degradation
of the inhibitory subunit IkBa, thus stimulating an autocrine
proangiogenic NF-kB-IL-8 pathway (Ve´gran et al., 2011). Lactate
also accelerates EC progenitor recruitment and differentiation
via the release of HIF-1a-dependent angiogenic factors (Milova-
nova et al., 2008). Blockade of lactate influx in ECs by monocar-
boxylate transporter 1 blockers, inhibiting lactate uptake in
tumor ECs, impedes HIF-1a-dependent angiogenesis (Son-
veaux et al., 2012).
Another paracrine metabolic signal is glutaminolysis-derived
ammonia, which induces autophagy and enhances tumor cell
survival at the expense of cell growth and proliferation (Eng
et al., 2010). Glutamine metabolism not only enhances the prolif-
eration and survival of oxygenated nutrient-rich tumor cells via
the anabolic replenishment of TCA cycle intermediates, but it
also helps nutritionally stressed neighbor tumor cells cope with
nutrient deprivation by inducing autophagy in order to preserve
cellular functions (Eng et al., 2010). The importance of autophagy
in EC biology remains poorly studied, though haplodeficiency of
the autophagy mediator Beclin-1 increases hypoxia-induced
angiogenesis associated with an increase in HIF-2a expression
and erythropoietin production (Lee et al., 2011). Moreover, dur-
ing retinal vascular development, the inhibition of autophagy
reduces hyaloid regression (Kim et al., 2010).
Another metabolic interaction between the tumor and its
stroma was recently described. ECs and tumor cells make direct
cell-cell contact and can exchange cellular components by
generating tunneling nanotubes. The transfer of mitochondria
from ECs to tumor cells via these nanotubes conferred tumor
resistance against chemotherapy (Pasquier et al., 2013). Thus,
besides providing the tumor with nutrients and oxygen, ECs
might also feed the tumor with their own metabolic machinery,
though further studies will be required to validate these findings.
Conclusions and Perspectives
In a field where >44,000 papers have been published on a single
molecule such as VEGF, it is surprising that <100 papers on how
ECs rewire their metabolism during vascular branching have
been reported. In order to grasp the importance of how meta-
bolism might influence EC behavior and vascular sprouting, it
will be necessary to first establish a metabolic roadmap of the
different metabolic pathways in the different EC subtypes
involved in vascular branching and to characterize how these
various metabolic pathways adapt during the various steps in
vessel sprouting. This will require state-of-the-art metabolic
flux analytic methods with stable isotope tracers in combination
with measurements of radioactive tracer flux analyses and
steady-state metabolite levels. It will also be intriguing to
characterize the metabolism of transformed hemangiomas and
angiosarcomas or study the effects of diabetes and hyper-
cholesterolemia on EC metabolism and sprouting. Another
appealing question is how ECs can regulate organismal meta-
bolism by differentiating into metabolically active adipocytes
(Gupta et al., 2012; Tran et al., 2012). Yet another unexplored
field is themetabolism-epigenome interaction. Doesmetabolism
epigenetically regulate vascular branching, similar to cancer
cells (Mazzarelli et al., 2007; Teperino et al., 2010; Yun et al.,
2012), or can the epigenome influence EC metabolism? Finding
an answer to these questions promises to be an exciting
endeavor.
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Vessel sprouting by endothelial cells (ECs) during angio-
genesis relies on a navigating tip cell and on proliferating
stalk cells that elongate the shaft. To date, only genetic
signals have been shown to regulate vessel sprouting.
However, emerging evidence indicates that the angio-
genic switch also requires a metabolic switch. Indeed,
angiogenic signals not only induce a change in EC me-
tabolism but this metabolic adaptation also co-deter-
mines vessel sprouting. The glycolytic activator PFKFB3
regulates stalk cell proliferation and renders ECs more
competitive to reach the tip. We discuss the emerging
link between angiogenesis and EC metabolism during
the various stages of vessel sprouting, focusing only on
genetic signals for which an effect on EC metabolism has
been documented.
Model of vessel sprouting
Blood vessels rapidly switch from a state of quiescence to
active sprouting in response to pro-angiogenic stimuli.
Specific EC subtypes orchestrate vessel sprouting. Navi-
gating tip cells (see Glossary) lead the vessel branch at the
vascular forefront, while proliferating stalk cells elongate
the shaft in the new sprout [1]. Neighboring sprouts anas-
tomose through interactions between filopodia on their
respective tip cells to form a new and perfused vessel
branch. ECs then regain their quiescent state (phalanx
cells) and are stabilized by the coverage of perivascular
mural pericytes [2]. Instead of providing a complete survey
of all known genetic molecules known to regulate vessel
sprouting (for which we refer to more historical overviews
[3–6]), we limit our overview here to molecules with known
effects on EC metabolism. We first describe the metabolic
pathways that ECs use to generate energy.
Energy generation in ECs
Glucose metabolism
In contrast to other healthy cells [7,8], ECs rely heavily
on glycolysis to generate energy (Figure 1) [8–10]. The
glycolysis rate in ECs is comparable to the rate measured
in various tumor cells [8]. Glycolysis is essential for ECs to
maintain homeostasis because nearly complete inhibition
of glycolysis with the glycolysis inhibitor 2-deoxy-D-glu-
cose (2-DG) induces cell death [8]. Notably, ECs rely mini-
mally on glucose oxidation and mitochondrial respiration
for ATP production [8,10]. Nonetheless, mitochondria rep-
resent a bioenergetic reserve to which ECs appeal under
stressed conditions [11].
Upon induction of sprouting by growth factors such
as vascular endothelial growth factor (VEGF), quiescent
Review
Glossary
Anastomosis: the process in which a tip cell meets and fuses with another tip
cell or a pre-existing blood vessel to form a lumenized loop that allows blood
flow.
Filopodia: thin (0.1–0.3 mm) long (10 mm) finger-like actin-rich plasma mem-
brane protrusions composed of parallel bundles of filamentous actin important
in cell migration, adhesion to the extracellular matrix, guidance towards
chemoattractants, cell–cell signaling, embryonic development, and wound
healing.
Glycocalyx: an interconnected gel-like network of membrane-bound proteo-
glycans and glycoproteins coating the luminal surface of ECs. This layer is
involved in the mechano-transduction of shear stress, the adherence of blood
cells, vascular permeability, and vessel wall homeostasis.
Glycolysis: the breakdown of glucose to pyruvate in 10 consecutive
cytoplasmic reactions to generate energy (ATP) and reducing power (NADH).
Hexosamine biosynthesis pathway (HBP): the metabolic pathway of which the
rate-limiting step is the transfer of the glutamine amido group to fructose-6-
phosphate. Ultimately, glucosamine-6-phosphate, the key precursor for O- and
N-linked protein glycosylation, is generated.
Lamellipodia: thin (0.1–0.2 mm) sheet-like protrusions behind the protruding
cell edge consisting of a densely branched filamentous actin network and that
are important in cell migration, substrate adhesion, macropinocytosis, and
phagocytosis.
Pentose phosphate pathway (PPP): the metabolic pathway that converts
glucose-6-phosphate to ribose-5-phosphate, a key intermediate of nucleotide
synthesis, with production of NADPH, and is important for several anabolic
processes and redox homeostasis.
Pericytes: (peri, around; cyte, cell) mural cells that cover blood microvessels
and share the vascular basement membrane. They provide support, ensure
vessel stability, and regulate permeability by direct physical contact and
paracrine signaling with ECs.
Phalanx cells: specialized ECs that are quiescent, lack filopodia, and are aligned
in a smooth tight cobblestone monolayer to ensure optimal blood flow and
stable perfusion of the surrounding tissues.
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3): a key reg-
ulatory bifunctional enzyme of the glycolytic flux. It has a high kinase:pho-
sphatase ratio (!740:1) and as such generates high amounts of fructose-2,6-
bisphosphate, the most potent allosteric activator of the rate-limiting glycolytic
enzyme phosphofructokinase-1 (PFK-1).
Spheroid assay: the use of in vitro established 3D EC aggregates to study EC
sprouting.
Stalk cells: specialized ECs that form the stalk of vascular sprouts. Stalk cells
trail behind tip cells, proliferate to elongate the stalk, and form a lumen. They
also prevent retraction of ECs.
Tip cells: specialized ECs located at the tip of the vascular sprout. These cells
are highly polarized, extend numerous filo- and lamellipodia with which they
probe the environment, and are key to both anastomosis and migration
because they direct the sprout.
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ECs increase their glycolysis rate by upregulating the
expression of, amongst others, glucose transporter 1
(GLUT-1: facilitates the transport of glucose across the
plasma membrane), lactate dehydrogenase-A (LDH-A:
converts pyruvate and NADH to L-lactate and NAD+),
and 6-phosphofructo-2-kinase/fructose-2,6-bisphospha-
tase-3 (PFKFB3) [8,9,12,13]. PFKFB3 synthesizes fruc-
tose-2,6-bisphosphate (F2,6P2), an allosteric activator of
phosphofructokinase-1 (PFK-1) and the most potent stimu-
lator of glycolysis [14]. Reducing glycolysis by PFKFB3 gene
silencing in ECs in vitro decreases EC migration and prolif-
eration, and impairs vessel sprouting in EC spheroid assays.
Furthermore, PFKFB3 gene inactivation in ECs in vivo
impedes vessel sprouting, branching, and outgrowth [8].
In view of the exposure of ECs to oxygen in the blood, the
importance of glycolysis in ECs might seem paradoxical
given that oxidative phosphorylation (OXPHOS) is more
efficient in generating ATP (approximately 20-fold more
ATP per glucose molecule [15]). However, this preference
can be explained by several reasons. First, endothelial
oxygen consumption would decrease the availability for
trans-endothelial transport to perivascular cells. Second,
the low oxygen-dependence of ECs might prepare them for
sprouting in hypoxic tissues. As such, ECs are able to
quickly sprout without the need to adapt to fluctuating
oxygen levels. This is further strengthened by the fact that
oxygen is more limiting than glucose in the tumor inter-
stitium (compared to glucose, oxygen has a higher diffu-
sion coefficient, but lower solubility and therefore also
lower available tissue concentration, resulting in a shorter
diffusion distance and steeper concentration gradient
from the vessel to the tissue [16–18]), and because ECs
are only susceptible to hypoxia when glucose is limiting
[19]. Third, lower oxidative metabolism results in less
oxidative stress. Fourth, when glucose availability is un-
limited, the glucose uptake and glycolysis rates can be
elevated to equal or even exceed the ATP production by
OXPHOS [10,15]. Finally, to sustain cell division and
migration, glycolysis intermediates can be shunted to
side-branches such as the pentose phosphate pathway
(PPP) and the hexosamine biosynthetic pathway (HBP).
The PPP is essential for nucleotide, lipid, and aromatic
amino acid synthesis as well as for anti-oxidant protection,
whereas the HBP is considered a nutrient sensor impor-
tant in protein glycosylation (Figure 1). The first and rate-
limiting step of the oxidative part of the PPP (oxPPP) is
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Figure 1. Endothelial cell (EC) metabolism. Schematic overview of the principal metabolic pathways and key enzymes in ECs. Glucose is taken up via the GLUT-1
transporter and subsequently phosphorylated by hexokinase. Quiescent ECs mainly rely on glycolysis to generate the energy needed to perform their functions, whereas
sprouting ECs even further upregulate their glycolysis rate. Glycolysis intermediates are shunted into side-branches for anti-oxidant defense and lipid synthesis (oxPPP) as
well as nucleotide synthesis (both oxPPP and non-oxPPP) and glycosylation purposes (HBP). Upon glucose scarcity, intracellular reserves can be broken down to sustain the
rate of glycolysis. ECs also use FAs and glutamine as energy sources via FAO and glutaminolysis respectively. The latter is required to maintain the functionality of the TCA
cycle (anaplerosis) as TCA cycle intermediates (e.g., citrate) exit for anabolic purposes. Abbreviations: 2-DG, 2-deoxy-D-glucose; DHAP, dihydroxyacetone phosphate;
F1,6P2, fructose-1,6-bisphosphate; F2,6P2, fructose-2,6-bisphosphate; F6P, fructose-6-phosphate; FABP4, fatty acid binding protein 4; FAs, fatty acids; FAO, fatty acid
oxidation; G1P, glucose-1-phosphate; G3P, glyceraldehyde-3-phosphate; G6P, glucose-6-phosphate; G6PDH, G6P dehydrogenase; GLS, glutaminase; Gln, glutamine; Glu,
glutamate; GlucN6P, glucosamine-6-phosphate; GLUT-1, glucose transporter 1; GlyP, glycogen phosphorylase; HBP, hexosamine biosynthetic pathway; HK, hexokinase; a-
KG, a-ketoglutarate; LDH-A, lactate dehydrogenase A; NADPH, nicotinamide adenine dinucleotide phosphate; (non-)oxPPP, (non-)oxidative branch of the pentose
phosphate pathway; OXPHOS, oxidative phosphorylation; 6-PG, 6-phosphogluconate; 6-PGL, 6-phosphogluconolactone; PFK-1, phosphofructokinase-1; PFKFB3, 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3; Pyr, pyruvate; R5P, ribulose-5-phosphate; TA, transaldolase; TCA, tricarboxylic acid; TKT, transketolase; UDP-
GlcNAc, uridine diphosphate N-acetylglucosamine.
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catalyzed by glucose-6-phosphate (G6P) dehydrogenase
(G6PDH), the plasma membrane localization and activity
of which is regulated by Src-mediated tyrosine phosphor-
ylation, and which plays a role in VEGF-mediated phos-
phorylation of Akt, VEGFR2, and eNOS, and EC responses
such as migration, proliferation, and tube formation
[20,21]. This is exemplified by a decrease in EC viability
and migration upon G6PDH inhibition by either a phar-
macological compound [22] or by high glucose levels [23].
Inhibition of transketolase, an enzyme involved in the non-
oxidative part of the PPP (non-oxPPP), also reduces EC
viability and migration [22]. Interestingly, inhibition of the
non-oxPPP has a more pronounced effect on EC viability
and migration than inhibition of the oxPPP, suggesting
that the reversible non-oxPPP compensates for the reduced
nucleotide synthesis via the oxPPP [22]. However, it is
worth mentioning that the relative importance of the
oxPPP in vitro might have been underestimated because
of the high glucose concentrations used in many studies,
which can suppress this branch [23]. Hence, both arms may
be important, but in different metabolic contexts.
Cells store energy in glycogen reservoirs that can be
used when extracellular glucose levels are insufficient to
meet the energy demand (Figure 1). VEGF signaling and
glucose deprivation induce glycogenolysis, which is the
breakdown of glycogen to G6P in ECs [22]. Further, phar-
macological inhibition of glycogen phosphorylase (and thus
of glycogenolysis) reduces EC viability and migration [22].
Although glycogenolysis-derived G6P only has a limited
contribution to glycolysis and energy production [24], it
may have more importance in glycolysis side-branches
such as the oxPPP. This has recently been shown to be
the case for tumor cells [25], but similar evidence in ECs is
still lacking. Overall, it is not yet clear which role glycogen
has in vascular sprouting.
Other metabolic pathways
In addition to glucose, ECs also use glutamine and fatty
acids as fuels (Figure 1). ECs are well-equipped to take up
and metabolize glutamine [26,27], a conditionally essential
amino acid [28]. Glutaminase catalyzes the conversion of
glutamine to glutamate, the first step of glutaminolysis
that yields a-ketoglutarate. The latter is used in the tri-
carboxylic acid (TCA) cycle to replace TCA cycle intermedi-
ates that have exited for anabolic purposes, thus
sustaining the functionality of the TCA cycle (anaplerosis)
[28]. In addition, glutamine is a key nitrogen source [28]
and contributes to improved viability of ECs under oxida-
tive stress [29]. The glutaminase activity of ECs has been
reported to be high [10] and its inhibition induces EC
senescence [30].
ECs can also obtain energy via the oxidation of fatty
acids from intra- and extracellular sources [31] (Figure 1).
Endothelial fatty acid oxidation (FAO) is increased in vitro
upon glucose deprivation through activation of AMP-acti-
vated protein kinase (AMPK), and upon stimulation with
carnitine [31] which is required for mitochondrial import of
fatty acids. VEGF-B is a poor angiogenic factor with rela-
tively restricted activity on coronary vessels, but VEGF-B
signaling via VEGF receptor 1 (VEGFR1)/neuropilin 1
increases the uptake and trans-endothelial transport of
fatty acids in ECs [32], but without influencing FAO in ECs
[33]. VEGF induces the expression levels of fatty acid
binding protein 4 (FABP4). This protein is involved in
uptake and trafficking of intracellular fatty acids, and
knockdown of FABP4 reduces EC proliferation [34], indi-
cating the importance of lipid metabolism.
Sprouting in a metabolically taxing environment: tip
versus stalk cells
Genetic signals
In response to hypoxia, the key angiogenic signal VEGF is
secreted in an attempt to restore tissue oxygenation by
promoting vessel sprouting. When VEGF reaches the vas-
cular front it binds to VEGF receptor 2 (VEGFR2) on ECs.
The EC exposed to the highest level of VEGF is selected to
become a tip cell. The current model of vascular branching
is based on the coordinated actions of migrating tip cells,
taking the lead at the vascular front, and proliferating
stalk cells elongating the newly developing branch [1], with
the fate of both cell types being dynamically interchange-
able rather than being permanently fixed [35] (Figure 2A).
The specification of tip versus stalk cells is dictated by
VEGF–Notch signaling. VEGFR2-activated tip cells ex-
press the Notch ligand Delta-like 4 (Dll4), which binds
to Notch receptors (single-pass transmembrane receptor
proteins) in neighboring ECs. This results in the release of
the receptor intracellular domain from the membrane,
Notch intracellular domain (NICD), which translocates
to the nucleus and regulates transcription of target genes
[36]. As a result, VEGFR2 expression is lowered whereas
levels of the VEGF trap VEGFR1 increase, which renders
ECs less responsive to VEGF, thus out-competing their
ability to become a tip cell and promoting a stalk cell fate
(Figure 2A). Dynamic tip cell–stalk cell fate interchange or
‘cell shuffling’ occurs at the vascular front to allow the ECs
with the highest VEGFR2 and lowest VEGFR1 expression
levels to occupy the tip position to ensure maximal fitness
of leading the sprout [35,37]. There are many more mole-
cules regulating tip versus stalk cell behavior, such as for
instance VEGF-C/VEGFR3, the angiopoietins, the TGF-b/
BMP9 receptor, and others [1], but these signals are not
known to affect EC metabolism in physiological conditions.
Metabolic signals
Recent findings indicate that VEGF increases glycolysis in
ECs by upregulating PFKFB3 mRNA and protein levels
before ECs start to proliferate, whereas Dll4-induced pro-
stalk Notch signaling induces the opposite effect [8], im-
plying that tip cells have higher glycolysis rates
(Figure 2B). Nonetheless, glycolysis is also essential for
stalk cell functions. Stalk cells actively proliferate and
therefore must generate high amounts of ATP and macro-
molecules that are derived from metabolic pathways, such
as the PPP, that branch off from the main glycolytic
pathway [7] (Figure 2C). However, Notch inhibits EC
proliferation in vitro. Hence, the growth-inhibitory func-
tion of Notch signaling must be overridden in vivo. Indeed,
Notch in stalk cells induces the expression of the Notch-
regulated ankyrin repeat protein (Nrarp), which in turn
enhances Wnt signaling to promote stalk cell proliferation
and vessel stability [38].
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Remarkably, overexpression of PFKFB3 overcomes
the pro-stalk activity of Notch signaling and promotes
stalk cells to adopt a tip cell behavior, both in EC
spheroid sprouting assays in vitro and in zebrafish vas-
cular branching in vivo, whereas silencing of PFKFB3
causes opposite effects in baseline conditions and upon
inhibition of Notch signaling [8]. These findings are
intriguing because no other genetic signal is so far
known to be able to overrule the pro-stalk activity of
Notch. Notably, over- or underexpression of PFKFB3 in
baseline conditions or in conditions favoring tip cell
behavior (upon inhibition of Notch signaling), or stalk
cell behavior (upon activation of Notch signaling), did not
alter the molecular signature of genes enriched in either
tip or stalk cells, indicating that PFKFB3 did not affect
tip and stalk cells through regulation of tip/stalk cell
signals [8]. Instead, these studies show for the first time
that metabolism (in this case, PFKFB3-driven glycolysis)
controls vessel branching in parallel to genetic signals
(Figure 3).
The metabolic status of the milieu into which new
vessels branch out complements the above mechanisms
via a feedback loop involving the NAD+-dependent deace-
tylase Sirtuin 1 (SIRT1). Upon sensing energy/fuel stress,
SIRT1 activity increases to deacetylate and to pre-destine
NICD for proteasomal degradation [39] (Figure 2A). These
findings might imply that the subsequent lowering of the
Notch-driven pro-stalk activity allows SIRT1 to direct tip
cells towards fuel-rich areas. Conversely, ECs with re-
duced SIRT1 activity fail to sense nutrient stress ade-
quately and are sensitized to pro-stalk Notch signaling,
resulting in impaired vessel growth [40].
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Figure 2. Genetic and metabolic determinants of tip, stalk and phalanx cell behavior. (A) Schematic representation of a vascular sprout with tip cell (green), stalk cell (blue)
and phalanx cell (yellow) and key genetic fate-determining factors. Upon sensing a VEGF gradient (red background) the tip cell induces Dll4 expression to activate Notch
signaling in the adjacent stalk cells (NICD release) and subsequently to decrease VEGFR2 and increase VEGFR1 levels to reduce VEGF sensitivity. SIRT1 translates energy
stress into NICD degradation resulting in tip cell behavior. (B–D) Different types of metabolism characterize the different EC subtypes; unknown metabolic changes are
indicated by question marks. For their migratory behavior, tip cells require large amounts of ATP. These are generated primarily by the high glycolytic flux (B). Stalk cells
divide to elongate the newly formed sprout and consequently require building blocks for rapid macromolecular synthesis. To obtain these precursors, NADPH is generated
in the oxPPP, nucleotides are synthesized via the non-oxPPP and/or oxPPP, and fatty acids and ATP are obtained by combining glycolysis and likely also anapleurotic
glutaminolysis (C). Phalanx cell metabolism ensures cellular homeostasis and provides energy for vital functions (D). Abbreviations: Dll4, Delta-like 4; FAO, fatty acid
oxidation; G6P, glucose-6-phosphate; Gln, glutamine; HBP, hexosamine biosynthetic pathway; NADPH, nicotinamide adenine dinucleotide phosphate; NICD, Notch
intracellular domain; (non-)oxPPP, (non-)oxidative branch of the pentose phosphate pathway; Pyr, pyruvate; SIRT1, Sirtuin1; TCA, tricarboxylic acid; VEGF, vascular
endothelial growth factor; VEGFR, VEGF receptor.
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The HBP pathway is another nutrient sensing pathway.
Inhibition of this pathway by 2-DG impedes angiogenesis,
which can be rescued by the N-linked glycosylation pre-
cursor mannose [41]. It is therefore tempting to speculate
that the HBP in ECs serves to translate nutrient stress
into adjusting blood vessel supply by generating N-acetyl-
glucosamine that post-translationally modifies and acti-
vates key angiogenic receptors. Indeed, VEGFR2 function
requires N-glycosylation [42]. Also noteworthy is the evi-
dence that the Notch response to the ligands Dll4 and
Jagged1 depends on the level of glycosylation of its extra-
cellular domain [43].
Metabolites can also control angiogenesis by acting as
bona fide signaling molecules. An example is the glycolysis
product lactate, which is taken up by ECs via the mono-
carboxylate transporter 1 (MCT1), and which mainly has a
signaling role because it seems to be only marginally
metabolized [44], at least at normal extracellular glucose
levels [24]. Once taken up by ECs, lactate competitively
inhibits the oxygen-sensing prolyl hydroxylase domain
protein 2 (PHD2), resulting in activation of hypoxia-induc-
ible factor 1a (HIF-1a) and a secondary increase in
VEGFR2 and basic fibroblast growth factor expression
[45]. PHD2 inhibition by lactate also triggers IkBa degra-
dation, releasing the transcription factor NF-kB to induce
the expression of the pro-angiogenic interleukin-8 [44].
Lactate also engages the PI3K/Akt pathway via upregula-
tion of the ligands and subsequent activation of three
receptor tyrosine kinases: Axl, the angiopoietin receptor
Tie2, and VEGFR2 [46]. Moreover, lactate signaling
induces VEGF expression [47] and reduces post-transla-
tional poly-ADP ribosylation of VEGF, thereby making it
more potent [48]. Lactate also promotes collagen and
proteoglycan matrix deposition [49], and stimulates EC
migration and capillary tube formation [44,49], although it
remains to be defined if matrix deposition induced by
lactate is causally linked to vessel sprouting. Finally,
lactate induces pro-angiogenic reactive oxygen species in
ECs [44].
Compartmentalization of glycolysis in F-actin-rich
lamellipodia
In ECs, both filopodia and lamellipodia have typical actin
networks (branched actin for lamellipodia versus aligned
filamentous actin for filopodia) that can be assembled within
minutes after growth factor stimulation [50]. The highly
dynamic nature of these structures relies on active actin
cytoskeleton remodeling and requires rapid generation and
instantaneous availability of large amounts of ATP; actin
polymerization for example is tightly linked to ATP hydro-
lysis [51–53]. Nevertheless, both filopodia and lamellipodia
are devoid of mitochondria [8], likely because mitochondria
(ranging in size from 0.5 to over 4 mm) cannot spatially fit
into the narrow filopodia and lamellipodia (!250 nm wide
and high, respectively) [54] (Figure 4A,C,D).
It is unlikely that sufficient amounts of ATP reach the
very tip of the filopodia (up to 10 mm in length) sufficiently
fast by diffusion from the distant perinuclear mitochondri-
al network; but, even so, it is conceivable that the continu-
ous protrusion and retraction of filopodia and lamellipodia
locally generates such a high ATP demand that ATP levels
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Figure 3. Metabolic switching between tip and stalk cells. (A) Metabolic glycolytic
signature of tip cells: tip cells are known to have high VEGF/VEGFR2 signaling.
Activation of VEGFR2 by VEGF upregulates PFKFB3 levels. PFKFB3 produces F2,6P2,
which is the most potent stimulator of PFK-1, a rate-limiting enzyme of the glycolytic
pathway. Consequently, the glycolysis rate is elevated which renders ECs more
competitive to reach the tip. By contrast, Dll4/Notch signaling, releasing NICD,
reduces glycolysis by lowering PFKFB3 expression, but this signaling pathway is less
active in tip cells. (B) Metabolic glycolytic signature of stalk cells: stalk cells are known
to have high Dll4/Notch signaling. Activation of Notch by Dll4 lowers PFKFB3-driven
glycolysis, thereby reducing competitiveness for the tip position. (C) Overexpression
of PFKFB3 induces switching from the stalk to the tip cell phenotype: Overexpression
of PFKFB3 in ECs, instructed to adopt a stalk cell phenotype by overexpression of
NICD, is capable of overcoming the stalk cell phenotype and increasing
the competitiveness of these cells for the tip position. Abbreviations: Dll4, Delta-
like 4; F2,6P2, fructose-2,6-bisphosphate; F6P, fructose-6-phosphate; NICD, Notch
intracellular domain; PFK-1, phosphofructokinase-1; PFKFB3, 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase-3; PFKFB3-OE, PFKFB3-overexpressing; VEGF,
vascular endothelial growth factor; VEGFR2, VEGF receptor 2 (the question mark
indicates that VEGFR2 probably mediates the VEGF response, but this needs to be
proven in the future).
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throughout the whole cell body might become compromised
during active lamellipodial and filopodial activity. To avoid
this, ECs compartmentalize glycolysis with the actin skel-
eton in cellular protrusions, mediating EC motility [8].
Various glycolytic enzymes contain actin-binding sites,
and binding to F-actin enhances their activity [55]. In
migrating ECs, both PFKFB3 and other glycolytic enzymes
– such as phosphoglycerate kinase and the pyruvate kinase
isoenzyme that generates ATP (PK-M1), rather than the
isoenzyme involved in biosynthesis of macromolecules
(PK-M2) – are enriched in the membrane ruffles at the
leading front of lamellipodia, and co-concentrate with F-
actin in these structures [8] (Figure 4B–D). Co-immuno-
precipitation experiments confirmed the PFKFB3-actin
interaction and showed that the fraction of PFKFB3 bound
to actin increases during EC motility [8]. Localizing glycol-
ysis-driven ATP production at the site of high ATP demand
during motility prevents the cell from succumbing to over-
all ATP depletion. Of note, compartmentalization of gly-
colysis in motile structures originated early in evolution:
for example, flagella in various microorganisms and ten-
tacles on members of the basal metazoan Hydra genus
[56,57]. Noteworthy in this respect, astrocytes localize
glycogen depots in their lamellipodial and filopodial exten-
sions, and glycolysis and glycogenolysis are essential for
astrocytic responses to increasing energy demand [58].
Phalanx cells: quiescent again
Genetic signals
ECs resume a quiescent state once the new vessel branch is
formed, and then adopt a cobblestone-like appearance that
resembles the ancient Greek military phalanx formation –
hence the term ‘phalanx cells’ [59]. These cells have few
filopodia, are non-proliferating, survive for years, migrate
poorly, and have an attenuated response to VEGF. Pha-
lanx cells express elevated levels of VEGFR1 to diminish
the pro-angiogenic signaling of VEGF [59] (Figure 2A).
Elevated signaling through Notch and the Tie2 receptor
in response to elevated levels of angiopoietin-1 between
ECs in trans additionally promotes EC quiescence [60,61].
Phalanx cells form a tight barrier and their monolayer
apposition allows conduction of blood flow, which by itself
is an important regulator of EC quiescence [1]. Vessel
stabilization is further enhanced by the deposition of a
basement membrane (BM) around quiescent ECs; this is in
part due to the fact that the BM component laminin a4
reduces tip cell specification by inducing Notch signaling
[62,63]. The expression of vascular endothelial cadherin
(VE-cadherin) and neuronal cadherin (N-cadherin) in qui-
escent ECs is crucial for cell–cell adhesion and optimal
endothelial barrier function, which are required for con-
trolled exchange of fluids and solutes between the blood-
stream and the neighboring tissue [64,65]. Lowering of pro-
angiogenic signals and increasing pro-quiescence mole-
cules promote ECs quiescence.
Metabolic signals
Less is known about the metabolic changes that precede or
accompany the EC’s switch to quiescence. Interestingly,
cell quiescence is often characterized by a higher level of
metabolism than previously anticipated [15]. Quiescent
ECs lower their glycolysis rate only by 40% – the propor-
tion of total glycolysis that is required for proliferation and
migration [8] (proliferation has been estimated to require a
30% increase in ATP production over quiescence [66]). The
remaining 60% of glycolysis in quiescent ECs ensures
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Figure 4. Compartmentalization of glycolysis with F-actin. (A) Schematic representation of a quiescent and a tip cell with mitochondria in the perinuclear region but, in the
case of the tip cell, not in filopodia or lamellipodia in which glycolytic activity is compartmentalized with F-actin. (B) Imaging of intracellular ATP levels in endothelial cells
(ECs) with a GO-Ateam ATP fluorescence resonance energy transfer (FRET) probe showing the presence of ATP in lamellipodia (white arrowheads). (C,D) Presence of
glycolytic activity in lamellipodia in the absence of mitochondria. EC double-stained for the glycolytic enzyme pyruvate kinase PK-M1 and the mitochondrial marker
Tomm20 (lamellipodia indicated by white arrowhead) (C) and merged with actin staining (D).
Review Trends in Endocrinology and Metabolism xxx xxxx, Vol. xxx, No. x
TEM-906; No. of Pages 8
6
cellular homeostasis and provides the necessary energy for
vital functions such as safeguarding barrier functions,
matrix deposition, and glycocalyx production [1,67]
(Figure 2D).
Concluding remarks and future perspectives
Over the past decade the angiogenesis field has gained an
enormous insight into the molecular players that control
the formation of vessels in physiological and pathological
conditions. Metabolism only recently entered the field of
angiogenesis as an important player. Although there are
some published data on the role of separate metabolic
pathways in ECs in vitro, a unifying view on how major
metabolic pathways converge in in vivo vessel branching is
almost nonexistent. Recent findings on how PFKFB3-driv-
en glycolysis determines vessel branching have only shown
the proverbial tip of the iceberg, and numerous outstand-
ing questions remain to be addressed (Box 1). For example,
a ‘metabolo-map’ of ECs in quiescence versus sprouting
state is largely missing, and other pathways besides gly-
colysis have been only minimally studied. Furthermore, it
is currently unknown how other branching signals (aside
from VEGF and Notch) control metabolism and vice versa.
The importance of metabolic communication between ECs
and other cell types, in normal tissues as well as in the
tumor microenvironment, remains unclear. In addition, it
is crucial to understand how the metabolic adaptations of
growing tumor vessels differ from those of rapidly prolif-
erating cancer cells because this will influence our thera-
peutic targeting strategies. Another outstanding question
is whether the definition of an underlying metabolic shift
that ECs undergo from quiescence to angiogenesis will
allow the development of new ‘anti metabolic anti angio-
genic’ agents, and whether targeting EC metabolism could
therefore provide a valuable alternative to overcome resis-
tance to currently approved anti angiogenic therapies,
without causing unacceptable toxicity. This is a timely
question given that novel anti angiogenic strategies with
fundamentally new mechanisms will likely aid in overcom-
ing toxicity and resistance issues of current anti angiogenic
therapies [3]. The generation of EC-specific metabolic
knockout animals, as well as the continuous improvement
of techniques to assess metabolic fluxes of ECs in quiescent
and growing vessels in vivo, will be required to answer all
these intriguing questions.
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Ectopic lipid deposition in muscle and liver is associated with the pathogenesis of type II diabetes. Hagberg
et al. (2012) report that targeting the vascular endothelial growth factor (VEGF)-B restores insulin sensitivity
and glucose tolerance by inhibiting endothelial-to-tissue lipid transport, opening promising avenues for
diabetes therapy.
Type II diabetes represents a formidable
unmet medical health problem with more
than 300 million people estimated to
be affected worldwide. Individuals with
diabetes have an elevated risk of vascular
disease (atherosclerosis, stroke) and
other complications. Diabetes-related
deaths are expected to rise at an alarming
speed over the coming years. Insulin
resistance has been linked to accumula-
tion of toxic lipid intermediates (ceram-
ides, diacylglycerol) in skeletal muscle
and liver. Hence, strategies prevent-
ing lipid deposition may offer therapeutic
benefit but are not widely available
(Samuel and Shulman, 2012). Hagberg
et al. (2012) demonstrate that targeting
the vascular endothelial growth factor B
(VEGF-B) restores insulin sensitivity and
prevents type II diabetes by reducing lipid
accumulation in muscle.
How can an angiogenic growth factor
like VEGF-B be linked to diabetes?
VEGF-B was one of the later members of
the VEGF family to be identified, and
its activity remains poorly understood
(Fischer et al., 2008). It is expressed in
the heart, skeletal muscle, and brown fat
and binds to VEGF receptor-1 (VEGFR1;
flt-1) and its coreceptor neuropilin-1
(NRP1). Genetic studies indicate that
VEGF-B’s angiogenic capacity is contex-
tual and largely restricted to the heart,
while pharmacological blockade inhibits
ocular angiogenesis. In cancer, VEGF-B
is, however, anti-angiogenic. Overall, its
activity is less potent than other traditional
angiogenic signals, but it induces strong
arterialization of the coronary vascula-
ture in rats (Bry et al., 2010). Importantly,
VEGF-B overexpression in mouse but
not in rat hearts leads to hypertrophy and
signs of mitochondrial lipotoxicity, sug-
gesting a possible role in cardiac metabo-
lism (Bry et al., 2010; Karpanen et al.,
2008). However, VEGF-B does not affect
mitochondrial function per se (Hagberg
et al., 2010; Karpanen et al., 2008). Rather,
it promotes lipid transport across the
endothelial barrier by upregulating the
fatty acid transport proteins (FATP)-
3/4 (Hagberg et al., 2010). Indeed, lipid
uptake and deposition in muscle were
reduced, and lipids were shunted to
white adipose tissue in VEGF-B-deficient
mice. Consequently, the fat mass and
body weight increased, and glucose
uptake to the heart was enhanced. These
initial observations prompted Hagberg
et al. (2012) to investigate the poten-
tial of anti-VEGF-B therapy for insulin
resistance.
In their follow-up study, Hagberg et al.
(2012) demonstrate that genetic defi-
ciency of VEGF-B in mouse models of
insulin resistance and type II diabetes,
including db/db diabetic mice (which
carry mutations in the leptin receptor
gene) andmice fedahigh-fat diet, reduces
lipid storage in muscle, heart, and
pancreas—but not liver. VEGF-B inhibi-
tion reduced plasma triglyceride and non-
esterified fatty acid levels and normalized
the HDL-c to LDL-c ratio, indicat-
ing a reduced risk for cardioavascular
pathology. However, the body weight of
VEGF-B-deficient mice on a high-fat diet
was increased. Nevertheless, VEGF-B
deficiency lowered blood glucose levels
without increasing insulin secretion and
restored insulin sensitivity and glucose
uptake in the muscle and heart.
Pharmacological inhibition of VEGF-B
via the administration of an anti-VEGF-B
antibody to db/db mice or rats fed a
high-fat diet largely phenocopied the
genetic findings and enhanced insulin
sensitivity. In a preventive setting (predia-
betic db/dbmice), VEGF-B blockade pre-
vented the development of hypergly-
cemia, reduced lipid uptake in muscle,
improved glucose tolerance, and pro-
tected against dyslipidemia. In a thera-
peutic setting (diabetic db/db mice),
VEGF-B inhibition halted the progres-
sion of hyperglycemia and muscle lipid
uptake. In addition, VEGF-B blockade
improved pancreatic islet morphology,
restored insulin and glucagon expression
in the islets, and reduced islet cell death
in both models. In another high-fat diet
rat model, coincident initiation of the
high-fat diet and anti-VEGF-B treat-
ment normalized glucose tolerance
and glucose-stimulated insulin secretion,
reduced glucose infusion and disposal
rates in a hyperinsulinemic/euglycemic
clamp study, and promoted glucose
uptake in muscle—evidence of improved
insulin sensitivity. These results support
the idea that VEGF-B regulates lipid
uptake by muscles. Given that VEGF-B
regulates lipid transport across the endo-
thelium, the findings suggest that the
endothelium acts as a prominent barrier
controlling muscle lipid uptake. Further-
more, blocking VEGF-B provides a mech-
anism to ameliorate or even prevent type
II diabetes (Figure 1).
As with any breakthrough, this study
raises a number of questions. For in-
stance, is the effect of VEGF-B on trans-
endothelial lipid transport the onlymecha-
nism? VEGF-B has a poor angiogenic
activity in healthy conditions, but an effect
of this growth factor on the vasculature
in conditions of insulin resistance remains
possible. Another question is whether
VEGF-B can control insulin signaling in
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endothelial cells, a process known to in-
crease insulin delivery to muscle (Kubota
et al., 2011). Since insulin also promotes
lipid uptake in muscle, VEGF-B’s activity
might also depend on effects on in-
sulin. It would also be interesting to test
whether endothelial deletion of NRP1 or
VEGFR1, known to reduce the levels of
the FATP4 transport protein in vitro
(Hagberg et al., 2010), phenocopies the
protective effects of VEGF-B blockade
in vivo. Given that different VEGF-B-
deficient mouse strains exhibit distinct
phenotypes in baseline conditions (Aase
et al., 2001; Bellomo et al., 2000), a con-
firmation of the antidiabetic phe-
notype in another VEGF-B-deficient strain
would strengthen the current findings. It
would also be interesting to explore if
VEGF-B has additional prodiabetic
effects through other changes in endothe-
lial cells, perhaps modifying endothelial
cell metabolism or endothelial-to-adipo-
cyte differentiation, or altering vascular
inflammation, a process known to modify
insulin sensitivity.
For anti-VEGF-B treatment to be clini-
cally relevant, the data of the Hagberg
et al. (2012) paper should be relevant
for humans. While the authors paid
great effort to test various rodent models,
genetic association studies have not
yet overwhelmingly identified VEGF-B as
a possible risk factor for diabetes in
humans. Another clinically relevant ques-
tion is whether therapeutic blockade
of VEGF-B therapy is safe. Deficiency of
VEGF-B is well tolerated. Nonetheless,
VEGF-B has been implicated in neuro-
genesis and neuroprotection (Poesen
et al., 2008) and ischemic cardiac re-
vascularization, raising the question
whether VEGF-B blockade might worsen
diabetic neuropathy or ischemic heart
disease. The role of VEGF-B in in-
hibiting tumor angiogenesis will also
deserve consideration. Overall, this work
places the endothelium and its regula-
tion by the VEGF-B ligand at the center
stage of tissue lipid homeostasis,
with promising therapeutic potential in
the context of diabetes, obesity, and
dyslipidemia.
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Pancreatic b cell failure is central in the pathogenesis of type 2 diabetes (T2D), but the mechanisms involved
remain unclear. Mahdi and colleagues (2012) couple global evaluation of gene expression with coexpression
network analysis of human islets from T2D patients to identify SFRP4 as an early mediator of b cell dysfunc-
tion in T2D.
Genome-wide association studies for
T2D have so far identified 65 susceptibility
loci for the disease (Morris et al., 2012),
but together these loci account for less
than 10% of the variance in disease
susceptibility. This contrasts with the situ-
ation in type 1 diabetes (T1D), where such
studies have identified 50 loci across the
human genome associated with T1D that
explain nearly 80% of the heritability
(Pociot et al., 2010). Other approaches
to identify basic mechanisms of disease
are therefore needed (Taneera et al.,
2012). Furthermore, direct studies of the
diseased human tissue—in the case of
T2D, human islets are the gold standard
given the central role of b cell dysfunc-
tion in its pathogenesis—are essential to
further our understanding of human dia-
betes (Cnop et al., 2005; Kahn, 2003). In
this issue of Cell Metabolism, Mahdi and
colleagues tackle these challenges by
performing microarray analyses of human
islets isolated from T2D and normoglyce-
mic individuals (Mahdi et al., 2012) (Fig-
ure 1). They identify a group of T2D-
associated genes related to interleukin-1
(IL-1), a proinflammatory cytokine, and
show that secreted frizzled-related pro-
tein 4 (SFRP4) is highly associated
with T2D.
Previous work already suggested that
IL-1b plays a role in b cell dysfunction
and death in T1D and T2D. However,
whereas a role for inflammation in b cell
loss is well established in the context of
T1D (Eizirik et al., 2009), it has remained
controversial for T2D (Cnop et al., 2005;
Donath et al., 2008). To explain local
IL-1b production in the islets of T2D indi-
viduals, one model proposed that IL-1b
production was induced by glucose,
leading to upregulation of the apoptotic
Fas receptor and ligand and b cell
‘‘suicide’’ (Donath et al., 2008), but this
was not confirmed by other groups (re-
viewed in Cnop et al., 2005). In recent
years a more nuanced view of inflamma-
tion in T2D islets emerged, consisting
of mild upregulation of cytokines and
chemokines in islets from T2D patients,
possibly mediated by increased circu-
lating concentrations of the free fatty
acid palmitate that induces islet IL-1b
and TNF-a expression (Igoillo-Esteve
et al., 2010). Experimental findings show
that this metabolic ‘‘T2D-like’’ stress
induces a mild inflammatory response,
representing around 5%–10% of the pro-
inflammatory response of human islets
exposed to ‘‘T1D-like’’ conditions (Cnop
et al., 2005; Igoillo-Esteve et al., 2010).
The role for this ‘‘low-intensity’’ innate
immunity-mediated inflammation in b cell
dysfunction and death in T2D remains
unclear. For instance, an IL-1 receptor
antagonist blocked palmitate-induced
chemokine expression, but failed to pre-
vent apoptosis (Igoillo-Esteve et al., 2010).
Using gene expression topology with
weighted gene coexpression network
analysis (in which coexpressed genes
are clustered into gene modules based
on their connectivity), Mahdi et al. now
identify a T2D-related gene module en-
riched for IL-1-related genes. Among the
most connected hub genes, the authors
identify SFRP4 as highly associated with
T2D, HbA1c (a measure of average
glucose levels over the past 2 months),
and insulin secretion (Figure 1). Subse-
quent functional studies then show that
the SFRP4 protein is induced by the cyto-
kine IL-1b. Furthermore, the authors show
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